Brind.

Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.

1 report, 1 independent Updated Aug 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Gilead Sciences Bank of America

Keep exploring

The entities involved

Gilead Sciences
American company
- FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.18:04
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.17:32
Bank of America
American multinational banking and financial services corporation
- Scotiabank raised its price target and Bank of America upgraded its rating on May 27, 2026, with MarketBeat aggregating the data.23:28
- Bank of America committed financing for the purchase in Illinois.22:53

Related events

Bank of America reported underperformance in earnings and failed to report suspicious transactions.Oct 14

Coverage

Newest first; wire copies grouped

Aug 8yahoo.com